Klimek, L. and Foerster-Ruhrmann, U. and Olze, H. and Beule, A. G. and Chaker, A. M. and Hagemann, J. and Huppertz, T. and Hoffmann, T. K. and Dazert, S. and Deitmer, T. and Strieth, S. and Wrede, H. and Schlenter, W. and Welkoborsky, H. J. and Wollenberg, B. and Becker, S. and Klimek, F. and Sperl, A. and Casper, I and Zuberbier, J. and Rudack, C. and Cuevas, M. and Hintschich, C. A. and Guntinas-Lichius, O. and Stoever, T. and Bergmann, C. and Pfaar, O. and Gosepath, J. and Groeger, M. and Beutner, C. and Laudien, M. and Weber, R. K. and Hildenbrand, T. and Hoffmann, A. S. and Bachert, C. (2022) Recommendations for Reviewing the Effectiveness and Documentation of the Course of Dupilumab in chronic Rhinosinusitis with Nasal polyps (CRSwNP) in the German Gealthcare System - Recommendations of the Medical Association of German Allergologists (AeDA) and the Working Groups Clinical Immunology, Allergology and Environmental Medicine and Rhinology and Rhinosurgery of the German Society for ENT Medicine, Head and Neck Surgery (DGHNOKHC). LARYNGO-RHINO-OTOLOGIE, 101 (11). pp. 855-865. ISSN 0935-8943, 1438-8685
Full text not available from this repository. (Request a copy)Abstract
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the nasal and paranasal mucosa. A Type-2 inflammation is described as the most common endotype. Since October 2019 the anti-IL-4/-IL-13 antibody dupilumab has been approved in Germany as an add-on therapy to intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps, when systemic corticosteroids alone or surgery do not provide adequate disease control. While recommendations for the use of dupilumab in CRSwNP exist at both national and international levels, until now it has not been adequately established, how therapy should be monitored and when it should be discontinued in the German Health Care System. Methods A literature search was performed analyzing previous data on the treatment of CRSwNP with dupilumab and to determine the available evidence by searching Medline, Pubmed, the national and international trial and guideline registries and the Cochrane Library. Human studies published in the period up to 05/2022 were included. Results Based on international literature and previous experience, recommendations are given by an expert panel for follow-up and possible therapy breaks, therapy intervals or termination of therapy when using dupilumab for the indication CRSwNP in the German health care system based on a documentation form. Conclusions Understanding the immunological basis of CRSwNP opens new non-surgical therapy approaches with biologics for patients with severe courses. The authors give recommendations for follow-up, possible therapy breaks, therapy intervals and a termination for dupilumab treatment as add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP that cannot be adequately controlled with systemic corticosteroids and/or surgical intervention.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ODOR IDENTIFICATION; POSITION PAPER; NORMATIVE DATA; DISCRIMINATION; BIOLOGICS; CRS; CRSwNP; Eosinophilie; Sinusitis; Typ-2-Inflammation; Dupilumab |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Hals-Nasen-Ohren-Heilkunde |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 12 Dec 2023 11:19 |
| Last Modified: | 12 Dec 2023 11:19 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58759 |
Actions (login required)
 |
View Item |
